Is the Safety and Efficacy of Calcium Antagonists now Established? Jørgen Fischer Hansen Legacy Pages: 145 - 147
Nifedipine After Acute Myocardial Infarction — Sola Dosis Facit Venenum*: Only the Dose Determines the Harm Franz H. Messerli Legacy Pages: 149 - 150
The Inappropriate Use of Hypothesis Testing to Infer Safety of Calcium Channel Blockers Frank E Harrell Jr. Legacy Pages: 151 - 153
Calcium Channel Blockers and the Risk of Cancer: A Preclinical Assessment Hans J. AhrErnst BomhardGerhard Schlüter OriginalPaper Pages: 157 - 169
Long-Term Mortality Follow-up of Hospital Survivors of a Myocardial Infarction Randomized to Nifedipine in the SPRINT Study Henrietta Reicher-ReissSolomon BeharUri Goldbourt OriginalPaper Pages: 171 - 176
Nifedipine and Cancer Mortality: Ten-Year Follow-up of 2607 Patients After Acute Myocardial Infarction Michael JonasUri GoldbourtHenrietta Reicher-Reiss OriginalPaper Pages: 177 - 181
Acute Myocardial Infarction Mortality Related to Use of Calcium Antagonists Before Admission to Hospital K. Landmarkå ReikvamI. Aursnes OriginalPaper Pages: 183 - 187
Selection of Drug Therapy in Stable Angina Pectoris Stefano SavonittoDiego Ardissino OriginalPaper Pages: 197 - 210
Safety, Tolerability, and Neurohormonal Changes of the Combination Captopril Plus Losartan in the Early Postinfarction Period: A Pilot Study Pietro Di PasqualeVincenzo BuccaSalvatore Paterna OriginalPaper Pages: 211 - 216
Increasing Nitroglycerin Release from Patches Enables Circumvention of Early Nitrate Tolerance Günther ReinigerGünter Lehmann OriginalPaper Pages: 217 - 224